Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Several technologies for hemoglobinopathies are being transferred to commercial partners
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
India currently hosts more than 10,075 biotech startups
Subscribe To Our Newsletter & Stay Updated
